Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gadolinium is a paramagnetic contrast agent primarily used in magnetic resonance imaging (MRI) to enhance the visibility of internal body structures. In the specific context of the clinical trial led by Li Nguyen for cervical dystonia, gadolinium is utilized as a tracer to evaluate the distribution, localization, and persistence of fluids injected into the tissue. The study compares the delivery of injections via the ASIS (Automated Subdermal Injection System) device, which targets the subdermal space and fascia, against traditional intramuscular injections. By measuring the persistent percentage of gadolinium on MRI at 6, 12, and 24 hours, the trial aims to demonstrate that subdermal delivery can prolong the presence of therapeutic agents like onabotulinumtoxinA (Botox) at the site of action while minimizing systemic spread and adverse reactions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gadolinium (Bayer).